Use of Alzheimer’s drug aducanumab raises concerns about Medicare spending

Medicare enrollment form


A UCLA-led cost analysis of the controversial new Alzheimer’s disease drug aducanumab shows that ancillary care services, such as additional MRIs and neurologist visits to monitor the potential brain swelling and bleeding associated with the medication, account for nearly 20% of total Medicare costs related to the drug, or $6,564 per patient per year.

With 1.1 to 5.7 million Medicare beneficiaries who have mild dementia or cognitive impairment identified as potentially eligible for the drug, these ancillary services could substantially increase annual Medicare spending, the analysis shows.


In June 2021, the U.S. Food and Drug Administration approved aducanumab to treat Alzheimer’s disease despite questions about evidence related to the drug’s efficacy and concerns about its high price. The drug’s manufacturer recently reduced the annual price of aducanumab from $56,000 to $28,200 per patient. (Previous spending estimates did not explicitly quantify aducanumab’s ancillary costs and did not incorporate this price reduction.)

Approximately 4 in 10 patients on aducanumab display what are known as amyloid-related abnormalities during brain imaging — a warning sign of bleeding or swelling — requiring multiple follow-up MRI scans and visits to the neurologist. In part due to these safety concerns, Medicare has preliminarily announced that it plans to restrict access to aducanumab to only those patients enrolled in clinical trials.


The researchers examined data on approximately 8,400 Medicare Part B beneficiaries age 65 and older and identified those with mild cognitive impairment or mild dementia who were potentially eligible to receive aducanumab. The study used validated cognitive measures and data from the nationally representative 2016 Health and Retirement Study, a longitudinal panel survey supported by the National Institute on Aging.


The ancillary costs associated with aducanumab could add further pressure on Medicare, raising questions of how to maximize the value of public dollars, particularly for a drug with uncertain benefit and a known risk of patient harm, the researchers said. They noted that the recent Centers for Medicare and Medicaid Services announcement of a large annual increase in Medicare premiums can be seen as just one example of aducanumab’s budgetary impact.


The study’s lead author is Dr. John Mafi, associate professor of medicine in the division of general internal medicine and health services research at the David Geffen School of Medicine at UCLA. Additional authors are Dr. Catherine Sarkisian, Mei Leng, Julia Cave Arbanas and Chi-Hong Tseng of UCLA; Cheryl Damberg of the RAND Corporation; and Dr. Bruce Landon of Harvard University.


The study is published the peer-reviewed journal JAMA Health Forum.


The research was supported by the National Institute on Aging, part of the National Institutes of Health (under awards R01AG070017 and K76AG064392). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Related Content



Media Contact

Enrique Rivero
[email protected]